Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025
Rhea-AI Summary
Absci (Nasdaq: ABSI) will report business updates and third quarter 2025 financial and operating results after market close on Wednesday, November 12, 2025.
Management will host a webcast and conference call on November 12, 2025 at 4:30 p.m. ET (1:30 p.m. PT) to discuss developments, results, and outlook. Live audio will stream on the company investor relations site at investors.absci.com, and the webcast will be archived for replay after the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ABSI declined 0.68%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
VANCOUVER, Wash. and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the company will report business updates and financial and operating results for the third quarter 2025 after market close on Wednesday, November 12, 2025.
Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook.
Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the event.
About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics. These include ABS-101, a potentially best-in-class antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
Media Contact
press@absci.com
FAQ
When will Absci (ABSI) release its Q3 2025 results?
What time is the Absci (ABSI) Q3 2025 earnings webcast on November 12, 2025?
Where can investors listen to Absci's (ABSI) November 12, 2025 webcast?
Will Absci (ABSI) provide a replay of the Q3 2025 webcast?
What topics will Absci (ABSI) management cover in the November 12, 2025 call?
How can shareholders submit questions during the Absci (ABSI) November 12, 2025 conference call?
